March 1, 2013
Bookmark and Share  




It has been a fast and furious month for the staff of HCSP/HCV Advocate.  You will find that there are some excellent articles in this month’s HCV Advocate Newsletter.  We also have updated the HCV Drug Pipeline—now you can click on the trial and it will take you to the listing on with more details of the study (see below).  If you like Twitter and Facebook you can follow me—I send out regular news stories, and you can also follow me as I travel across the train people about hepatitis C.



HCV Advocate Newsletter: March, 2013

In This Issue:

2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies. Hepatitis B is a complicated disease to understand and manage. Christine's monthly review provides much needed information to stay up to date and live healthy with hepatitis B:

  • Few Ethnic Minorities at Risk of Hepatitis B Are Screened for Infection

  • Even Asian-American College Students Unaware of Hepatitis B Risk

  • Vaccine's Effectiveness May Wane Over Time Unless Surface Antibodies Remain

  • Sexually Transmitted Infections Affect Young Adults and Carry High Costs

  • Declining HBsAg Levels During Interferon Treatment Forecasts Success

  • Entecavir and Tenofovir Safe in Patients with Severe Cirrhosis

  • Adding Tenofovir to Telbivudine Boosts Its Effectiveness in Hard-to-Treat Patients

  • Some Infants Are Infected with HBV Prior to Birth

  • Breastfeeding Does Not Increase Risk of Mother-to-Child HBV Infection

  • Tenofovir Effective After Lengthy Treatment in Those With Drug Resistance


3. HCSP Guides: Updated!

Be sure to check out our recently redesigned and updated HCSP Guides:


4. Clinical Trials Postings: Updated!
Be sure to check out the latest clinical trial postings at Just click on the links to the Drug Companies at the top and to see which drugs are in trials right now, where the trials are, and how to register for one.


5. Don't forget to check out our updated schedule for HCV Trainings. To find out what's coming to your neighborhood click here.

Coming in March:


Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 


6. Don't forget to check out our updated schedule for HCV Trainings. To find out what's coming to your neighborhood click here.


7. Top News (Blog) from the hepatitis blog includes: 

Top News

Addressing Hepatitis C Disparities in the African American Community
February 28

Help Lift the Ban on Funding of Needle Exchange
February 27

Hepatitis C testing offered at Health Fair this year
February 27

Chronic HCV linked to hypertension, congestive heart failure
February 27

Scientists are not divided over device that 'remotely detects hepatitis C'
February 27

SAMHSA Announces New Funding Announcement for Rapid Hepatitis C Screening in Drug Treatment Programs
February 26

The Hidden Costs of Health Care
February 25

Hepatitis C Outbreak Prompts Legislation
February 22

Postoperative peg-interferon plus ribavirin associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma, with comments by Alan Franciscus
February 22

Regulatory Application has now been filed for Simeprevir (TMC435) in Japan for the treatment of genotype 1 hepatitis C patients
February 22

Clinical Effects of Viral Relapse after Interferon Plus Ribavirin in Patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus—with Comments by Alan Franciscus
February 21

Antioxidant Improves Donated Liver Survival Rate to More Than 90%
February 21



Follow us on Twitter


Join us on Facebook
Hcvadvocate Hcsp


 and much, much more…..




Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate
Editor-in-Chief, HBV Advocate

**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.